| Title |
Cancer Drugs Fund 2.0: A Missed Opportunity?
|
|---|---|
| Published in |
PharmacoEconomics, March 2016
|
| DOI | 10.1007/s40273-016-0403-2 |
| Pubmed ID | |
| Authors |
Christopher McCabe, Ash Paul, Greg Fell, Mike Paulden |
X Demographics
The data shown below were collected from the profiles of 21 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 5 | 24% |
| New Zealand | 2 | 10% |
| Canada | 1 | 5% |
| Australia | 1 | 5% |
| Pakistan | 1 | 5% |
| Unknown | 11 | 52% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 62% |
| Scientists | 6 | 29% |
| Practitioners (doctors, other healthcare professionals) | 1 | 5% |
| Science communicators (journalists, bloggers, editors) | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 5% |
| Unknown | 19 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 20% |
| Researcher | 4 | 20% |
| Student > Doctoral Student | 2 | 10% |
| Student > Master | 2 | 10% |
| Professor | 2 | 10% |
| Other | 3 | 15% |
| Unknown | 3 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 35% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 15% |
| Economics, Econometrics and Finance | 2 | 10% |
| Social Sciences | 1 | 5% |
| Decision Sciences | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 6 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 July 2017.
All research outputs
#2,729,736
of 25,342,911 outputs
Outputs from PharmacoEconomics
#230
of 1,994 outputs
Outputs of similar age
#42,295
of 307,039 outputs
Outputs of similar age from PharmacoEconomics
#5
of 26 outputs
Altmetric has tracked 25,342,911 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,994 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 307,039 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.